Trane Technologies plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Trane Technologies plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $14.78B | Feb 21, 2012 |
| FY2010 | Dec 31, 2010 | $14.08B | Feb 22, 2011 |
| FY2009 | Dec 31, 2009 | $13.20B | Feb 26, 2010 |
| FY2009 | Dec 31, 2008 | $13.23B | Feb 26, 2010 |
| FY2009 | Dec 31, 2007 | $8.76B | Feb 26, 2010 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.32B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $19.84B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $17.68B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $15.99B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $14.14B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $12.45B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $13.08B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $12.34B | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $14.20B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $13.51B | Feb 12, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $14.20B | Feb 12, 2018 |
| FY2017 | Dec 31, 2016 | $13.51B | Feb 12, 2018 |
| FY2017 | Dec 31, 2015 | $13.30B | Feb 12, 2018 |
| FY2016 | Dec 31, 2014 | $12.89B | Feb 13, 2017 |
| FY2015 | Dec 31, 2013 | $12.35B | Feb 12, 2016 |
| FY2014 | Dec 31, 2012 | $11.99B | Feb 13, 2015 |
| FY2013 | Dec 31, 2011 | $12.76B | Feb 14, 2014 |
| FY2012 | Dec 31, 2010 | $14.00B | Feb 14, 2013 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.92B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $2.57B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $2.02B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.76B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $1.42B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $854.90M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.41B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.34B | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $1.30B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.48B | Feb 12, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.97B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.50B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $2.89B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $2.42B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.02B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.53B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.67B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.51B | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $1.67B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.60B | Feb 12, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $347.60M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $309.60M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $252.30M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $211.20M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $193.50M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $165.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $174.20M | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $166.70M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $210.80M | Feb 18, 2020 |
| FY2017 | Dec 31, 2016 | $207.90M | Feb 12, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.74B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.58B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $2.96B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $2.55B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $2.45B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $2.27B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $2.32B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $2.25B | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $2.72B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $2.60B | Feb 12, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.19B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.15B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $2.39B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.50B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $1.59B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $1.44B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.92B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $1.41B | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $1.52B | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $1.52B | Feb 12, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $370.60M | Feb 6, 2025 |
| FY2024 | Dec 31, 2023 | $300.70M | Feb 6, 2025 |
| FY2024 | Dec 31, 2022 | $291.80M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $223.00M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $146.20M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $205.40M | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $284.70M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $221.30M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $182.70M | Feb 12, 2019 |
| FY2017 | Dec 31, 2015 | $249.60M | Feb 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $21.42B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $20.15B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $19.39B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $18.08B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $18.06B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $18.16B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $20.49B | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $17.91B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $18.17B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $17.40B | Feb 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.82B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $12.66B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $12.37B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $11.98B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $11.79B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $11.73B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $13.18B | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $10.85B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $10.97B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $10.68B | Feb 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.58B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $7.46B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $7.00B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $6.09B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $6.26B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $6.41B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $7.27B | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $7.02B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $7.14B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $6.64B | Feb 12, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.46B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $6.13B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $6.10B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $5.50B | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $5.50B | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $5.34B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $5.13B | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $5.10B | Feb 9, 2021 |
| FY2018 | Dec 31, 2017 | $5.94B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $5.66B | Feb 12, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.42B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $9.79B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $9.13B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $8.32B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $8.35B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $8.50B | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $9.73B | Feb 9, 2021 |
| FY2019 | Dec 31, 2018 | $9.44B | Feb 18, 2020 |
| FY2018 | Dec 31, 2017 | $8.90B | Feb 12, 2019 |
| FY2017 | Dec 31, 2016 | $8.02B | Feb 12, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.76B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.59B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.10B | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.22B | Feb 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.16B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $3.29B | Feb 7, 2022 |
| FY2021 | Dec 31, 2019 | $1.28B | Feb 7, 2022 |
| FY2021 | Dec 31, 2018 | $878.40M | Feb 7, 2022 |
| FY2020 | Dec 31, 2017 | $1.52B | Feb 9, 2021 |
| FY2019 | Dec 31, 2016 | $1.71B | Feb 18, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.62B | Feb 5, 2026 |
| FY2024 | Dec 31, 2024 | $4.77B | Feb 6, 2025 |
| FY2023 | Dec 31, 2023 | $4.78B | Feb 8, 2024 |
| FY2022 | Dec 31, 2022 | $4.84B | Feb 10, 2023 |
| FY2021 | Dec 31, 2021 | $4.84B | Feb 7, 2022 |
| FY2020 | Dec 31, 2020 | $5.27B | Feb 9, 2021 |
| FY2019 | Dec 31, 2019 | $5.57B | Feb 18, 2020 |
| FY2018 | Dec 31, 2018 | $4.09B | Feb 12, 2019 |
| FY2017 | Dec 31, 2017 | $4.06B | Feb 12, 2018 |
| FY2016 | Dec 31, 2016 | $4.06B | Feb 13, 2017 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 13 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | 5 | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | 5 | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | 5 | Feb 12, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 12 | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | 8 | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | 7 | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | 5 | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | 3 | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | 5 | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | 5 | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | 5 | Feb 12, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 249.00M | Feb 6, 2025 |
| FY2024 | Dec 31, 2023 | 251.70M | Feb 6, 2025 |
| FY2023 | Dec 31, 2022 | 253.30M | Feb 8, 2024 |
| FY2010 | Dec 31, 2010 | 328.19M | Feb 22, 2011 |
| FY2010 | Dec 31, 2009 | 320.62M | Feb 22, 2011 |
| FY2009 | Dec 31, 2008 | 370.81M | Feb 26, 2010 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $837.30M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $757.50M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $683.70M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $620.20M | Feb 6, 2025 |
| FY2023 | Dec 31, 2021 | $561.10M | Feb 8, 2024 |
| FY2022 | Dec 31, 2020 | $507.30M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $510.10M | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $479.50M | Feb 9, 2021 |
| FY2019 | Dec 31, 2017 | $430.10M | Feb 18, 2020 |
| FY2018 | Dec 31, 2016 | $348.60M | Feb 12, 2019 |